INTRODUCTION
Volume loss under the eyes results in a hollowed out appearance
below the eyes. This appearance is referred to
as “infraorbital hollowsâ€. It may be caused by one or more
of the following: (1) loss of infraorbital subcutaneous fat, (2) protrusion
of infraorbital fat pads (“bagsâ€), and (3) sagging of the upper
cheek.1-4 These events, often the sequellae of normal aging processes,
are more pronounced in some individuals than in others.
Correction of infraorbital hollows is an increasingly important
nonsurgical procedure for the restoration of the aging face.5 In
the clinical literature, studies of hyaluronic acid (HA) soft tissue
fillers for treatment of infraorbital hollows have of late regularly
appeared.5, 6-18 Several of these articles have addressed the use of
primarily small particle HA, or Restylane, for infraorbital hollows
and/or tear troughs,13,16,19 Juvéderm,20 and at least one reports on
the use of Perlane.11 Other more recent publications speak broadly
of HA fillers, including Belotero Balance.21-23 In 2013, a supplement
on Belotero Balance was published in Plastic Surgery in which
authors provided a detailed review of the clinical literature as well
as a commentary on the application vis-Ã -vis other HAs.24,25
The ideal filler for this region of the face should be “malleable,â€
so that any uneven or raised areas can be smoothed out with
gentle finger pressure immediately following injection. Belotero Balance® (Merz North America, Greensboro, NC), manufactured
to create a cohesive polydensified matrix hyaluronic acid
(CPMHA), was approved by the FDA in 2011 for the correction
of moderate to severe nasolabial folds and wrinkles. Among the
fillers currently available in the US, Belotero Balance exhibits the
least stiffness (lowest G-prime value) and lowest resistance to
deformation (or complex modulus value).26 The lowest stiffness
is helpful for injection precision and the lowest resistance to deformation
will help the filler conform to the injection-site contour
as well as disperse uniformly with digital pressure or massage
immediately following injection. These two properties help make
it attractive for use in the infraorbital area, where any overcorrection
or irregularity is readily apparent. In this paper, investigators
report their findings in 46 patients on the use of Belotero Balance
in the infraorbital region, with evaluations out to 40 weeks.
Study Objective
The objective of this study was to determine the safety and efficacy
of Belotero Balance for the correction of infraorbital hollows.
Patient Population
Of the 49 patients enrolled, 46 (87.8%) completed the study. Of
these patients, 38 were female and 8 were male. Age range of subjects
was from 31 years to 67 years, with a mean age of 51 years.